Glenmark is proud to bring a revolution in diabetes management by introducing for the first time in the world, its researched, global, SGLT2 inhibitor - Remogliflozin . Remogliflozin has been extensively researched across countries and is backed by 26 clinical studies involving more than 2500 patients . With the launch of Remogliflozin, Glenmark is poised to bring a new paradigm in diabetes treatment for better patient outcome . Glenmark invites you for an interactive webinar on 19th May 2019 from 7:00 pm onwards . In this webinar, Chairperson Dr. Bipin Kumar Sethi Dr. V Dayasagar Rao Speakers Dr.
Bipin Kumar Sethi will talk about “Paradigm Shift in The Management of T2DM” Dr. R N Mehrotra will talk about “Remogliflozin- Clinical Evidence & Therapeutic Place in Type 2 Diabetes Mellitus” Panelists Dr. Bipin Kumar Sethi Dr. V Dayasagar Rao Dr. R N Mehrotra Dr. E A Padma Kumar Dr. Deepak…
